Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference53 articles.
1. European Commission. Rare diseases – what are they? (cited June 2018)
https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en
2. Jaffe A, Zurynski Y, Beville L, Elliott E. Call for a national plan for rare diseases. J Paediatr Child Health. 2010;46(1–2):2–4.
3. Walker C, Mahede T, Davis G, Miller L, Girschik J, Brameld K, et al. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genet Med. 2016;19(5):546–52.
4. Kakkis E, O’Donovan M, Cox G, Hayes M, Goodsaid F, Tandon P, et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J Rare Dis. 2015;10(1):16.
5. Department of Health, Western Australia. WA Rare Diseases Strategic Framework 2015–2018. Perth: Office of Population Health Genomics, Public Health Division, Department of Health, Western Australia; 2015. (cited June 2018)
http://ww2.health.wa.gov.au/Reports-and-publications/WA-Rare-Diseases-Strategic-Framework-2015-2018
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献